US Patent

US7763615 — Ecteinascidin analogs for use as antitumour agents

Method of Use · Assigned to Pharmamar SA · Expires 2029-12-13 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a class of ecteinascidin analogs as antitumor agents.

USPTO Abstract

Derivatives of ecteinascidin 736 of general formula (I) wherein the groups R 1 , R 2 , R 3 , R 4 and R 5 are each independently selected from the group consisting of H, OH, OR′, SH, SR′, SOR′, SO 2 R′, C(═O)R′, C(═O)OR′, NO 2 , NH 2 , NHR′, N(R′) 2 , NHC(O)R′, CN, halogen, ═O, substituted or unsubstituted C 1 -C 25 alkyl, substituted or unsubstituted C 2 -C 18 alkenyl, substituted or unsubstituted C 2 -C 18 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic; wherein X is independently selected of OR′, CN, (═O), or H; wherein each of the R′ groups is independently selected from the group consisting of H, OH, NO 2 , NH 2 , SH, CN, halogen, ═O, C(═O)H, C(═O)CH 3 , CO 2 H, substituted or unsubstituted C 1 -C 25 alkyl, substituted or unsubstituted C 2 -C 18 alkenyl, substituted or unsubstituted C 2 -C 18 alkynyl, substituted or unsubstituted aryl; wherein m is 0, 1 or 2; and wherein n is 0, 1, 2, 3, or 4, and their use as antitumoral agent.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4299 Zepzelca

Patent Metadata

Patent number
US7763615
Jurisdiction
US
Classification
Method of Use
Expires
2029-12-13
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Pharmamar SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.